EP2766727B1 - Assay device comprising an optical filter and a method of assaying - Google Patents
Assay device comprising an optical filter and a method of assaying Download PDFInfo
- Publication number
- EP2766727B1 EP2766727B1 EP12787472.5A EP12787472A EP2766727B1 EP 2766727 B1 EP2766727 B1 EP 2766727B1 EP 12787472 A EP12787472 A EP 12787472A EP 2766727 B1 EP2766727 B1 EP 2766727B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- assay device
- analyte
- pathway
- light
- zone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Not-in-force
Links
- 238000003556 assay Methods 0.000 title claims description 69
- 230000003287 optical effect Effects 0.000 title claims description 45
- 238000000034 method Methods 0.000 title claims description 13
- 239000012491 analyte Substances 0.000 claims description 74
- 239000000463 material Substances 0.000 claims description 65
- 230000037361 pathway Effects 0.000 claims description 64
- 230000005540 biological transmission Effects 0.000 claims description 11
- 239000002699 waste material Substances 0.000 claims description 9
- 239000002243 precursor Substances 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 5
- 239000004033 plastic Substances 0.000 claims description 5
- 229920003023 plastic Polymers 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 13
- CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 10
- 238000005286 illumination Methods 0.000 description 6
- 238000000862 absorption spectrum Methods 0.000 description 5
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000013077 target material Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000000295 emission spectrum Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000004886 process control Methods 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000005670 electromagnetic radiation Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 108010087904 neutravidin Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000012125 lateral flow test Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
- G01N33/525—Multi-layer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/84—Systems specially adapted for particular applications
- G01N21/8483—Investigating reagent band
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
- G01N33/54389—Immunochromatographic test strips based on lateral flow with bidirectional or multidirectional lateral flow, e.g. wherein the sample flows from a single, common sample application point into multiple strips, lanes or zones
Definitions
- This invention relates generally to devices for bio-assay, pathogen, or molecular analysis, and to systems and methods for such analysis.
- the invention may be employed for bio-assays such as sandwich or competitive assays, e.g. immunoassays, for example fluorescence immunoassays (FIA).
- sandwich or competitive assays e.g. immunoassays, for example fluorescence immunoassays (FIA).
- Optical systems may be used to determine the presence, concentration or quantity of a target material or analyte in a test sample, quantitatively, semi-quantitatively or qualitatively.
- Optical systems may be used successfully, they suffer from a number of disadvantages. For example, they may require the use of relatively expensive equipment in order to perform the assay which may not be appropriate for some determinations or may not be available for some tests. For example, in some cases a qualitative determination of the presence' of an analyte may be sufficient whereas in other cases a quantitative determination may be necessary.
- tests may be of limited performance leading to tests having to be repeated.
- US2005/243321 A1 discloses a system that employs transmission-based detection techniques to determine the presence or concentration of an analyte within a test sample is provided.
- the optical detection system contains a chromatographic-based assay device that is positioned in the electromagnetic radiation path defined between an illumination source and detector. To enhance the sensitivity and signal-to-noise ratio of the system without significantly increasing costs, the distance between the illumination source and/or detector and the assay device is minimized.
- the illumination source and/or detector may also be positioned directly adjacent to the assay device.
- the system may be selectively controlled to reduce reliance on external optical components, such as optical filters or diffusers.
- the present invention provides a stand-alone assay device according to independent claim 1.
- the device may be employed for performing lateral flow tests or other forms of test such as flow-through devices and tests and microfluidic tests, indeed for any test that may be used for competitive or sandwich assays.
- This form of device may be employed in a number of ways. For example, it may be used together with an illumination and reading device in order to detect very small quantities of the analyte, or to perform quantitative tests on the analyte. However, in other circumstances the device may be a free standing or stand-alone device which may be employed without a reader in order to perform a less sensitive or qualitative test simply to determine the presence or absence of an analyte.
- the invention provides an arrangement for performing an assay according to claim 8.
- the invention provides a method of performing a test on an analyte according to independent claim 9.
- the assay device will include a label zone where a quantity of the label matenal is located, the label zone preferably being located on the pathway between the application zone and the capture zone so that, on application of the analyte the analyte will contact the label material, and the analyte and label material will together pass along the pathway to the capture zone.
- the label material may be mixed with the analyte beforehand, i.e., before applying the analyte to the device.
- Figure 1 shows schematically an assay device or test strip 1 and a reader 2 for enabling a quantitative or qualitative test to be performed on an analyte.
- a quantity of an analyte may be applied to one part of the device so that it can flow along a pathway in the device toward the opposite end thereof, and the device can be inserted into the reader 2 in order to obtain an output indicative of the quantity of the analyte on an output display 4 of the reader.
- the device comprises a generally transparent bottom cover 6 and a generally transparent top cover 8 which is located over the bottom cover and bonded thereto.
- the top cover 8 may include an area 9 on which a physical label may be affixed for information.
- the top and bottom covers may be transparent over their entire surface which enables them to be made from a single piece of plastics material. However, this is not essential, and it is necessary only for the top and bottom covers to be transparent in the region of pathways 10 along which the analyte will be caused to travel.
- the top and bottom covers enclose a plurality of pathways 10, two in this case, one for detection of the analyte and a control pathway, although other numbers may be used if, for example, a number of different analytes are to be detected using the same assay device.
- the pathways are formed from a porous material such as nitrocellulose.
- the pathways 10 extend from a sample dispensing zone or application zone 14 (see Figure 5 ) at one end region of the device where the analyte may be dispensed during the test to the opposite end region so that the analyte will travel along the pathway during the test.
- the thickness of the transparent top cover 8 may be reduced along a reduced thickness region 11 extending along part of the pathway 10 in order to allow the pathway to be viewed more easily through the transparent top cover 8.
- a wash collection reservoir 12 may be provided in the opposite end region of the device so that wash may be applied to the pathways to cause the analyte to flow along the pathway to the wash collection reservoir.
- a quantity of a label which as used herein includes any label precursor, may be provided at a label and primary receptor zone 16 on one or both of the pathways at a position between the sample dispensing zone and the waste zone or wash collection reservoir so that, as the analyte travels along the pathway, the label will be taken up by the analyte and will travel along the pathway together with the analyte.
- a specific bond may be formed between the label and the analyte, for example a bond between an antibody pair, an antigen pair, a DNA bond or any other bond.
- the label material may be biotinylated so that it will form a biotin-avidin bond with the analyte. The presence of the analyte may thus be detected by subsequently observing the presence of the label.
- the label is described in greater detail below.
- a capture zone 18 Downstream of the label and primary receptor zone 16 along the pathway is a capture zone 18 (see Figure 5 ) where a quantity of capture material is located.
- the capture material is bound to the pathway and will bind to any of the analyte that passes along the pathway so that the analyte will be retained in one position on the pathway 10 corresponding to the capture material.
- the capture material may also be biotinylated so that the analyte will be bound to the pathway by a biotin-avidin bond.
- a quantity of the analyte is dispensed into a dispensing port 20 (see Figure 2 ) that is located over one of the pathways above the application zone 14.
- the analyte may be dispensed by means of a pipette, dropper or other appropriate device as shown in Figure 7 in order to dispense a defined quantity of the analyte.
- a quantity of a control analyte may be applied to a dispensing port 21 located over the application zone of the other pathway 10.
- the control analyte may be one that exhibits a known strong bond with the label material and capture material, and a control label may be present (which may be the same or different to the label employed in the other pathway) in order to exhibit a strong, defined signal when the device is illuminated in order to enable the operator to confirm that analyte has been dispensed during the assay.
- control analyte/control label bond and control analyte/control capture material bond may be based on a biotin-avidin bond or a similar bond as mentioned above.
- the analyte will wet the pathways located under the dispensing ports 20 and 21 as shown by the hatched regions in Figure 8 .
- the analyte will travel along the pathway by capillary action taking the label from the label zone 16 of Figure 5 with it.
- the analyte and label will bond to the pathway as shown by the hatched region in Figure 9 .
- a process control zone 26 Downstream of the capture zone 18 on the pathway or each of the pathways 10 is a process control zone 26 which is located below a process control window 28 in the top surface of the device. After application of analyte it will travel along the pathway by capillary action, and will hydrate the pathway causing a colour change. The pathway can be viewed through the process control windows 28 in order to observe the colour change and ensure that the analyte and label have travelled along the pathway to and beyond the capture zone 18.
- a wash may then be applied to cause the analyte, control analyte and label to flow along the pathways toward the wash collection reservoir 12.
- the wash may be applied in any number of ways. For example it may be applied to the sample dispensing port, or an alternative port, by means of a pipette, dropper or other device that will dispense a quantity of wash into the dispensing ports 20 and 21.
- a wash dispensing reservoir 24 may be provided in the device at the end of the device opposite the wash collection reservoir, or on a side of the device.
- the dispensing reservoir may be in the form of a bladder, blister pack or sachet which may be punctured in order to cause the wash to flow along the pathways.
- the reader may be designed to receive the assay device and be provided with a ridge or protuberance that will apply a stress to the wash dispensing reservoir and rupture it when the device is inserted into the reader so that the wash is applied automatically on insertion of the assay device into the reader.
- the assay device may be ready to be illuminated and read as soon as the device is washed.
- a further processing step may be necessary in order to activate the label (which may be referred to herein at times as a label precursor).
- FDA fluorescein diacetate
- it may be necessary to hydrolyse the precursor and/or to heat it in order to release the label.
- This operation may be performed at any appropriate time.
- an acid or base hydrolysis step is necessary, the appropriate acid or base may be applied either before or after application of the analyte, for example along with the wash step.
- the wash in the wash reservoir may have a pH that will cause the hydrolysis so that the activation step occurs automatically with the washing step.
- the assay device is now ready to be illuminated in order to detect the presence of analyte.
- the reader comprises a housing having an orifice or slot 35 therein for receiving the assay device 1, a light source 32 for example an LED or an incandescent lamp, located on one side of the slot for receiving the assay device, and an optical sensor for example a PIN diode or an avalanche photodiode located on the opposite side of the slot so that light from the light source will pass through the device.
- the light source may be powered by a standard battery 36 or other power source such as a transformer.
- the reader includes a conventional signal processor 38 for controlling light source drive electronics 40, a detector amplifier circuit 42 and a display circuit for the display 4.
- the assay device is preferably provided with a polarizing profile in order to ensure that the device cannot be inserted into the reader upside down or back to front.
- a polarizing profile may include a cut corner 29 which will cooperate with a corresponding corner in the reader.
- a part-circular cut out 30 may be included in one end of the device to ensure which end of the device is inserted.
- Many other forms of polarizing profile may be employed.
- the assay device may be illuminated as soon as the pathways have been washed, but in other cases it may be necessary to wait for a period of time before illumination, in which case a timer may be provided in the reader in order to ensure that the device is illuminated and read at the appropriate time.
- a timer may be provided in the reader in order to ensure that the device is illuminated and read at the appropriate time.
- the term "light” has been used herein, it will be appreciated that this is because the device is intended for reading visually. Any electromagnetic radiation may in principle be used to read the device, and the light will not necessarily be visible light, although this is preferred.
- the light may have components in the infrared or ultraviolet spectrum and may even have a spectrum in which the radiation is predominantly in wavelength ranges outside the visible wavelength range. However, as explained below, the light is preferably in the visible range.
- the label material located in the device may be one that will emit or modify light, at least when activated, so that the light emitted from the device due to the presence of the analyte will differ from the illuminating light.
- One surface of the device that receives the light only after it has passed through the label material is formed from a material that provides a first optical filter that will allow transmission of the light emitted or modified by the label material and will block light of at least one other wavelength range. This has the advantage that the effect of the label material is enhanced by removing at least some of the background light that is not affected by the label material.
- the other surface of the device that is to say the surface that will be illuminated by the light source during the reading stage, is also formed from a material that forms a second optical filter that has a different optical transmission characteristic from that of the first optical filter.
- the second optical filter will allow transmission of light of a shorter wavelength range than that of the first optical filter, for example the second optical filter may be a blue filter while the first optical filter may be a green filter.
- the filters will be such that together they will block light in substantially the entire visible light range.
- the long wavelength cut off of the second filter will be substantially the same as, or in the region of the short wavelength cut off of the first filter, so that the combination of the two filters will block substantially all visible light.
- the filters provided in the top and bottom of the assay device may be formed from any appropriate material, for example glass, plastics materials, thin film materials or they may be holographic filters or interference filters.
- an interference filter a dielectric coating is deposited in layers to allow only the desired wavelengths to pass while light of other wavelengths is reflected.
- the materials should be relatively inexpensive and so plastics filters are preferred.
- Figure 4 shows the absorption spectrum of fluorescein (graph A) which may be employed as a label material with a maximum at 492nm and its emission spectrum (graph B) with a maximum at 517nm.
- labels that can affect the wavelength of light such as fluorescent or phosphorescent materials together with optical filters on both sides of the assay device as described above (rather than the filters being associated with the reader) has the important advantage that it is possible, at least for a number of tests (for example many qualitative tests or where a high concentration of analyte is present) to dispense with the optical reader so that it is possible simply to hold the assay device up to a source of white light, for example the sun, and observe the presence or absence of any bands on the pathway caused by the fluorescent label.
- a source of white light for example the sun
- any of a number of label materials may be employed in the device. These may include simple coloured dyes or pigments that will affect the absorption spectrum of the analyte, but they are preferably fluorescent, phosphorescent or chemiluminescent materials. Examples of materials that may be employed as labels are disclosed in U.S. patent No. 7,796,266 .
- label as used herein can include precursors of a label where appropriate, so that some additional step or steps may be needed before the material functions as an optical label, for example acid or base hydrolysis may be required or the application of heat or both.
- the label material comprises lipid walled capsules, optionally having a polymer outer shell, containing a signal precursor.
- lipid walled capsules optionally having a polymer outer shell, containing a signal precursor.
- the capsules may be formed from the lipid DSPE-PEG2000 Amine and sodium dodecyl sulphate (SDS) and may contain fluorescein diacetate (FDA) as the signal precursor.
- SDS lipid DSPE-PEG2000 Amine and sodium dodecyl sulphate
- FDA fluorescein diacetate
- These capsules may be activated by being placed in an activation solution having a pH of approximately 10.1 and then heating.
- the pH of the activation solution is chosen to be just below the pH value at which the FDA in this type of capsule will undergo rapid hydrolysis to fluorescein without additional heat.
- an embodiment of the method according to the invention includes the step of illuminating the assay device from one side with white light or ambient and viewing the device from the other side in order to detect absorption bands in the pathway caused by absorption of light by the fluorescent label material. In this method it is not necessary to use a reader with a dedicated light source and detector.
- any second optical filter on the side of the device that is illuminated although it may be advantageous to do so in order to reduce the intensity of light passing through the assay device that is not affected by the absorption by the fluorescent or phosphorescent material, and so increase the proportion of light that is absorbed by the fluorescent or phosphorescent material.
- encapsulated signal generating molecules to generate detectable signals for extremely low concentrations of target material gives exceptional utility to the assay device of the present invention.
- point of care determinations can be made even though the user may not have access to a reader.
- the device can be used in remote locations, in field applications, or in any circumstances where access to a reader is not available.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Description
- This invention relates generally to devices for bio-assay, pathogen, or molecular analysis, and to systems and methods for such analysis. The invention may be employed for bio-assays such as sandwich or competitive assays, e.g. immunoassays, for example fluorescence immunoassays (FIA).
- Optical systems may be used to determine the presence, concentration or quantity of a target material or analyte in a test sample, quantitatively, semi-quantitatively or qualitatively. However, while such systems may be used successfully, they suffer from a number of disadvantages. For example, they may require the use of relatively expensive equipment in order to perform the assay which may not be appropriate for some determinations or may not be available for some tests. For example, in some cases a qualitative determination of the presence' of an analyte may be sufficient whereas in other cases a quantitative determination may be necessary. Furthermore, such tests may be of limited performance leading to tests having to be repeated. In addition, there is a general desire to reduce the cost of the equipment used for the assay, and to reduce the time taken to perform the test. In other cases, it may not be desired to perform such an assay under laboratory conditions but instead it may be necessary to perform the test in the field with the minimum of equipment.
-
US2005/243321 A1 discloses a system that employs transmission-based detection techniques to determine the presence or concentration of an analyte within a test sample is provided. Specifically, the optical detection system contains a chromatographic-based assay device that is positioned in the electromagnetic radiation path defined between an illumination source and detector. To enhance the sensitivity and signal-to-noise ratio of the system without significantly increasing costs, the distance between the illumination source and/or detector and the assay device is minimized. The illumination source and/or detector may also be positioned directly adjacent to the assay device. In addition, the system may be selectively controlled to reduce reliance on external optical components, such as optical filters or diffusers. - According to one embodiment, the present invention provides a stand-alone assay device according to independent claim 1.
- The device may be employed for performing lateral flow tests or other forms of test such as flow-through devices and tests and microfluidic tests, indeed for any test that may be used for competitive or sandwich assays.
- This form of device may be employed in a number of ways. For example, it may be used together with an illumination and reading device in order to detect very small quantities of the analyte, or to perform quantitative tests on the analyte. However, in other circumstances the device may be a free standing or stand-alone device which may be employed without a reader in order to perform a less sensitive or qualitative test simply to determine the presence or absence of an analyte.
- According to another embodiment, the invention provides an arrangement for performing an assay according to
claim 8. - According to yet another embodiment, the invention provides a method of performing a test on an analyte according to
independent claim 9. - Normally, the assay device will include a label zone where a quantity of the label matenal is located, the label zone preferably being located on the pathway between the application zone and the capture zone so that, on application of the analyte the analyte will contact the label material, and the analyte and label material will together pass along the pathway to the capture zone. However, in the broadest aspect of the invention, it is not necessary for the label material to be located on the pathway of the device when the assay device is supplied, and it is possible for the label material to be supplied separately and to be applied to the device along with the analyte. Alternatively, the label material may be mixed with the analyte beforehand, i.e., before applying the analyte to the device.
- The invention will now be described by way of example only with reference to the drawings, in which:
-
Figure 1 is a schematic perspective view of a test device according to the present invention, and a reader; -
Figure 2 is a more detailed view of the test device ofFigure 1 ; -
Figure 3 is an exploded view of the test device shown inFigure 2 showing the various components thereof; -
Figure 4 is a graphical representation of emission and absorption spectra of one form of label material that may be employed in the device; -
Figure 5 is a view of the device with the top surface removed to show the inner details thereof; -
Figure 6 is a schematic view of the device and reader; -
Figure 7 is a view of the device during a test according to the invention; -
Figure 8 shows the device at one point during the test; and -
Figure 9 shows the device at another point during the test. -
Figure 1 shows schematically an assay device or test strip 1 and areader 2 for enabling a quantitative or qualitative test to be performed on an analyte. In one embodiment of the invention, a quantity of an analyte may be applied to one part of the device so that it can flow along a pathway in the device toward the opposite end thereof, and the device can be inserted into thereader 2 in order to obtain an output indicative of the quantity of the analyte on anoutput display 4 of the reader. - The form of the assay device is shown in more detail in
Figures 2 and 3 . As shown inFigure 3 , the device comprises a generally transparent bottom cover 6 and a generallytransparent top cover 8 which is located over the bottom cover and bonded thereto. Thetop cover 8 may include anarea 9 on which a physical label may be affixed for information. The top and bottom covers may be transparent over their entire surface which enables them to be made from a single piece of plastics material. However, this is not essential, and it is necessary only for the top and bottom covers to be transparent in the region ofpathways 10 along which the analyte will be caused to travel. The top and bottom covers enclose a plurality ofpathways 10, two in this case, one for detection of the analyte and a control pathway, although other numbers may be used if, for example, a number of different analytes are to be detected using the same assay device. The pathways are formed from a porous material such as nitrocellulose. Thepathways 10 extend from a sample dispensing zone or application zone 14 (seeFigure 5 ) at one end region of the device where the analyte may be dispensed during the test to the opposite end region so that the analyte will travel along the pathway during the test. In this form of assay device, the thickness of thetransparent top cover 8 may be reduced along a reducedthickness region 11 extending along part of thepathway 10 in order to allow the pathway to be viewed more easily through thetransparent top cover 8. Awash collection reservoir 12 may be provided in the opposite end region of the device so that wash may be applied to the pathways to cause the analyte to flow along the pathway to the wash collection reservoir. - A quantity of a label, which as used herein includes any label precursor, may be provided at a label and
primary receptor zone 16 on one or both of the pathways at a position between the sample dispensing zone and the waste zone or wash collection reservoir so that, as the analyte travels along the pathway, the label will be taken up by the analyte and will travel along the pathway together with the analyte. A specific bond may be formed between the label and the analyte, for example a bond between an antibody pair, an antigen pair, a DNA bond or any other bond. In one example, where the analyte is avidin, streptavidin or neutravidin, the label material may be biotinylated so that it will form a biotin-avidin bond with the analyte. The presence of the analyte may thus be detected by subsequently observing the presence of the label. The label is described in greater detail below. - Downstream of the label and
primary receptor zone 16 along the pathway is a capture zone 18 (seeFigure 5 ) where a quantity of capture material is located. The capture material is bound to the pathway and will bind to any of the analyte that passes along the pathway so that the analyte will be retained in one position on thepathway 10 corresponding to the capture material. In the case of a device that is used to detect avidin, streptavidin or neutravidin mentioned above, the capture material may also be biotinylated so that the analyte will be bound to the pathway by a biotin-avidin bond. - During the assay, a quantity of the analyte is dispensed into a dispensing port 20 (see
Figure 2 ) that is located over one of the pathways above theapplication zone 14. The analyte may be dispensed by means of a pipette, dropper or other appropriate device as shown inFigure 7 in order to dispense a defined quantity of the analyte. A quantity of a control analyte may be applied to adispensing port 21 located over the application zone of theother pathway 10. The control analyte may be one that exhibits a known strong bond with the label material and capture material, and a control label may be present (which may be the same or different to the label employed in the other pathway) in order to exhibit a strong, defined signal when the device is illuminated in order to enable the operator to confirm that analyte has been dispensed during the assay. - In the case of a quantitative analysis, it is possible to use the signal generated from the control label as a reference against which the signal from the analyte/label signal may be compared. For example the control analyte/control label bond and control analyte/control capture material bond may be based on a biotin-avidin bond or a similar bond as mentioned above. Initially the analyte will wet the pathways located under the
dispensing ports Figure 8 . The analyte will travel along the pathway by capillary action taking the label from thelabel zone 16 ofFigure 5 with it. At thecapture zone 18, the analyte and label will bond to the pathway as shown by the hatched region inFigure 9 . Downstream of thecapture zone 18 on the pathway or each of thepathways 10 is aprocess control zone 26 which is located below aprocess control window 28 in the top surface of the device. After application of analyte it will travel along the pathway by capillary action, and will hydrate the pathway causing a colour change. The pathway can be viewed through theprocess control windows 28 in order to observe the colour change and ensure that the analyte and label have travelled along the pathway to and beyond thecapture zone 18. - A wash may then be applied to cause the analyte, control analyte and label to flow along the pathways toward the
wash collection reservoir 12. The wash may be applied in any number of ways. For example it may be applied to the sample dispensing port, or an alternative port, by means of a pipette, dropper or other device that will dispense a quantity of wash into the dispensingports wash dispensing reservoir 24 may be provided in the device at the end of the device opposite the wash collection reservoir, or on a side of the device. The dispensing reservoir may be in the form of a bladder, blister pack or sachet which may be punctured in order to cause the wash to flow along the pathways. In another form of arrangement where a reader is employed as described below, the reader may be designed to receive the assay device and be provided with a ridge or protuberance that will apply a stress to the wash dispensing reservoir and rupture it when the device is inserted into the reader so that the wash is applied automatically on insertion of the assay device into the reader. - Once the wash has been applied, substantially no material should be present on the pathway other than the analyte bound to the capture zone and the label that is bound to the analyte.
- With many forms of capture and label arrangement the assay device may be ready to be illuminated and read as soon as the device is washed. However, in some cases a further processing step may be necessary in order to activate the label (which may be referred to herein at times as a label precursor). For example, where some forms of fluorescent label are used as described below, and in particular where fluorescein diacetate (FDA) is used, it may be necessary to hydrolyse the precursor and/or to heat it in order to release the label. This operation may be performed at any appropriate time. For example, if an acid or base hydrolysis step is necessary, the appropriate acid or base may be applied either before or after application of the analyte, for example along with the wash step. In this case, the wash in the wash reservoir may have a pH that will cause the hydrolysis so that the activation step occurs automatically with the washing step.
- The assay device is now ready to be illuminated in order to detect the presence of analyte. This may be achieved by means of a reader as shown in
Figures 1 and6 . The reader comprises a housing having an orifice orslot 35 therein for receiving the assay device 1, alight source 32 for example an LED or an incandescent lamp, located on one side of the slot for receiving the assay device, and an optical sensor for example a PIN diode or an avalanche photodiode located on the opposite side of the slot so that light from the light source will pass through the device. The light source may be powered by astandard battery 36 or other power source such as a transformer. The reader includes aconventional signal processor 38 for controlling lightsource drive electronics 40, adetector amplifier circuit 42 and a display circuit for thedisplay 4. - The assay device is preferably provided with a polarizing profile in order to ensure that the device cannot be inserted into the reader upside down or back to front. As will be appreciated, inserting the device upside down will cause any excitation wavelengths to be filtered out by the longer wavelength filter on the upper surface of the device. Such a polarizing profile may include a
cut corner 29 which will cooperate with a corresponding corner in the reader. Also, a part-circular cut out 30 may be included in one end of the device to ensure which end of the device is inserted. Many other forms of polarizing profile may be employed. - In some cases, the assay device may be illuminated as soon as the pathways have been washed, but in other cases it may be necessary to wait for a period of time before illumination, in which case a timer may be provided in the reader in order to ensure that the device is illuminated and read at the appropriate time. For example, in the case of base hydrolysed FDA, it may be advantageous to wait for a period of from 100 to 500 seconds after hydrolysis before illumination.
- Although the term "light" has been used herein, it will be appreciated that this is because the device is intended for reading visually. Any electromagnetic radiation may in principle be used to read the device, and the light will not necessarily be visible light, although this is preferred. The light may have components in the infrared or ultraviolet spectrum and may even have a spectrum in which the radiation is predominantly in wavelength ranges outside the visible wavelength range. However, as explained below, the light is preferably in the visible range.
- The label material located in the device may be one that will emit or modify light, at least when activated, so that the light emitted from the device due to the presence of the analyte will differ from the illuminating light.
- One surface of the device that receives the light only after it has passed through the label material, in this embodiment the
top cover 8, is formed from a material that provides a first optical filter that will allow transmission of the light emitted or modified by the label material and will block light of at least one other wavelength range. This has the advantage that the effect of the label material is enhanced by removing at least some of the background light that is not affected by the label material. - The other surface of the device, that is to say the surface that will be illuminated by the light source during the reading stage, is also formed from a material that forms a second optical filter that has a different optical transmission characteristic from that of the first optical filter.
- The second optical filter will allow transmission of light of a shorter wavelength range than that of the first optical filter, for example the second optical filter may be a blue filter while the first optical filter may be a green filter. Especially the filters will be such that together they will block light in substantially the entire visible light range. In other words, in the preferred form of device, the long wavelength cut off of the second filter will be substantially the same as, or in the region of the short wavelength cut off of the first filter, so that the combination of the two filters will block substantially all visible light.
- The filters provided in the top and bottom of the assay device may be formed from any appropriate material, for example glass, plastics materials, thin film materials or they may be holographic filters or interference filters. In an interference filter, a dielectric coating is deposited in layers to allow only the desired wavelengths to pass while light of other wavelengths is reflected. However, in view of the fact that the filters are provided on the assay device which will be a consumable item, the materials should be relatively inexpensive and so plastics filters are preferred.
- If the label material is one such as a fluorescent or phosphorescent material which exhibits a Stokes shift between its absorption spectrum and emission spectrum, it is possible for the filters formed by both surfaces of the device to block substantially all light but allow fluorescence or phosphorescence caused by the label to be detected. For example,
Figure 4 shows the absorption spectrum of fluorescein (graph A) which may be employed as a label material with a maximum at 492nm and its emission spectrum (graph B) with a maximum at 517nm. As can be seen the use of a second optical filter having a long wavelength cut off in the region of 500nm and a second optical filter having a short wavelength cut off in the region of 500nm will allow substantially the entire fluorescence from fluorescein to be observed against a dark background. - The use of labels that can affect the wavelength of light such as fluorescent or phosphorescent materials together with optical filters on both sides of the assay device as described above (rather than the filters being associated with the reader) has the important advantage that it is possible, at least for a number of tests (for example many qualitative tests or where a high concentration of analyte is present) to dispense with the optical reader so that it is possible simply to hold the assay device up to a source of white light, for example the sun, and observe the presence or absence of any bands on the pathway caused by the fluorescent label.
- According to the broadest aspect of the invention, any of a number of label materials may be employed in the device. These may include simple coloured dyes or pigments that will affect the absorption spectrum of the analyte, but they are preferably fluorescent, phosphorescent or chemiluminescent materials. Examples of materials that may be employed as labels are disclosed in
U.S. patent No. 7,796,266 . In addition, the term "label" as used herein can include precursors of a label where appropriate, so that some additional step or steps may be needed before the material functions as an optical label, for example acid or base hydrolysis may be required or the application of heat or both. - According to one preferred embodiment, the label material comprises lipid walled capsules, optionally having a polymer outer shell, containing a signal precursor. Such forms of label material are disclosed in international patent application No.
WO 02/12888 A2 - For example, the capsules may be formed from the lipid DSPE-PEG2000 Amine and sodium dodecyl sulphate (SDS) and may contain fluorescein diacetate (FDA) as the signal precursor. These capsules may be activated by being placed in an activation solution having a pH of approximately 10.1 and then heating. The pH of the activation solution is chosen to be just below the pH value at which the FDA in this type of capsule will undergo rapid hydrolysis to fluorescein without additional heat.
- Capsules such as those disclosed in international patent application No.
WO 02/12888 A2 - For example, for the FDA-containing capsules, it is conjectured that it is this very high degree of fluorescence generated by the FDA-containing capsules when activated that enables the FDA-containing capsules to be employed in an assay device according to an embodiment of the present invention employing relatively cheap and low performance optical filters located on a consumable component such as the assay device. According to
U.S. patent No. 7,796,266 referred to above, it is a large Stokes shift, for example from 100nm to 350nm, that minimizes the need for expensive, high precision filters in the optical detection in order to eliminate background interference. However fluorescein employed according to an embodiment of the present invention has a Stokes shift of only about 25 to 28nm. - In fact, the use of fluorescent or phosphorescent labels, and especially labels formed from the FDA-containing capsules referred to above, can have the effect that the assay device can exhibit an absorption spectrum of fluorescein when exposed to white or ambient light. Thus, according to yet another aspect, an embodiment of the method according to the invention includes the step of illuminating the assay device from one side with white light or ambient and viewing the device from the other side in order to detect absorption bands in the pathway caused by absorption of light by the fluorescent label material. In this method it is not necessary to use a reader with a dedicated light source and detector. Nor is it necessary to include any second optical filter on the side of the device that is illuminated although it may be advantageous to do so in order to reduce the intensity of light passing through the assay device that is not affected by the absorption by the fluorescent or phosphorescent material, and so increase the proportion of light that is absorbed by the fluorescent or phosphorescent material.
- The ability of encapsulated signal generating molecules to generate detectable signals for extremely low concentrations of target material gives exceptional utility to the assay device of the present invention. When such encapsulated signal generating molecules are incorporated into or used with the assay device, point of care determinations can be made even though the user may not have access to a reader. Hence, the device can be used in remote locations, in field applications, or in any circumstances where access to a reader is not available.
Claims (15)
- A stand-alone assay device (1) for enabling a test to be performed on an analyte, the assay device (1) having an application zone (14) for application of a quantity of the analyte, a waste zone (12), and a pathway (10) for allowing passage of the analyte from the application zone (14) to the waste zone (12);
the assay device (1) having a first cover (6) on a first side of the pathway (10) and a second cover (8) on a second side of the pathway (10) opposite the first side;
the first cover (6) providing a first optical filter for allowing transmission of light emitted or modified by a label material and for blocking light of at least one other wavelength range; and
the second cover (8) forming a second optical filter, the second optical filter having a different optical transmission characteristic from that of the first optical filter;
the assay device (1) including a quantity of the label material which will emit or modify light at least when activated and which will bind to the analyte, the pathway (10) also including a capture zone (18) located between the application zone (14) and the waste zone (12) that has a quantity of capture material which is bound to the pathway (10) and which will bind to analyte that passes along the pathway (10) so that the analyte will be bound to the pathway (10), the assay device (1) being adapted to be illuminated from said second side of the pathway by a light source (32) separate from the assay device (1) such that light emitted or modified by the label material located in the pathway (10) is detectable at the first side of the pathway. - An assay device (1) as claimed in claim 1, wherein each of the first and second covers (6,8) comprises a single piece of plastics material.
- An assay device (1) as claimed in claim 1, wherein the first optical filter and the second optical filter together block substantially all light.
- An assay device (1) as claimed in claim 1 wherein the second optical filter will allow transmission of light of shorter wavelength than light transmitted by the first optical filter.
- An assay device (1) as claimed in claim 4 wherein the label material is a fluorescent or phosphorescent material or a precursor thereof, and the first optical filter will allow transmission of light only after modification by the label material.
- An assay device (1) as claimed in claim 1 wherein the first optical filter will allow transmission of light of different wavelengths that correspond to light emitted or modified by different label materials.
- An assay device (1) as claimed in claim 1 which includes a plurality of pathways (10) extending generally in parallel with one another from an application zone (14) to a waste zone (12), the pathways (10) containing different capture materials to enable a test to be performed on a plurality of different analytes.
- An arrangement for performing an assay, which comprises an assay device (1) as claimed in claim 1 and a reader (2) for detecting an output from the assay device (1), said reader (2) comprising a body having an orifice (35) that is capable of receiving the assay device (1), a light source (32) for illuminating the assay device (1) from said second side thereof once it has been received in the reader (2), a terminal for receiving a power source (36) for the light source (32), an optical detector (34) located in the body for detecting light that has been emitted from the first side of the assay device, and a detector (38,42) for detecting the optical power of light detected by the optical detector (34).
- A method of performing a test on an analyte, by means of a stand-alone assay device (1) having an application zone (14) for application of the analyte, a waste zone (12), and a pathway (10) for allowing passage of the analyte from the application zone (14) to the waste zone (12), the assay device (1) having a first cover (6) on a first side of the pathway (10) and a second cover (8) on a second side of the pathway (10) opposite the first side, the pathway (10) also including a capture zone (18) located between the application zone (14) and the waste zone (12) that has a quantity of capture material which is bound to the pathway (10) and which will bind to any analyte, which method comprises:applying a quantity of the analyte to the application zone (14) and allowing the analyte to pass along the pathway (10) to and beyond a capture zone (18) where the pathway (10) includes a quantity of capture material which will bind the analyte to the pathway (10);causing the analyte to contact, either before or after it has reached the capture zone (18), a quantity of a label material which will emit or modify light at least when activated and which will bind to the analyte so that the analyte and label material will be bound to the pathway (10) at the capture zone (18);applying a quantity of a wash to the application zone (14) in order to cause excess analyte and label material to flow along the pathway (10) to the waste zone (12); andilluminating the assay device (1) from the second side of the pathway anddetecting light that is emitted or modified by the label material from the first side of the pathway, said first cover (6) of the assay device (1) providing a first optical filter for allowing transmission of light emitted or modified by the label material and for blocking light of at least one other wavelength range so that detection of the light will indicate the presence or quantity of the analyte, and said second cover of the assay device (1) forming a second optical filter having a different optical transmission characteristic from that of the first optical filter.
- A method as claimed in claim 9, wherein each of the first and second covers (6,8) comprises a single piece of plastics material.
- A method as claimed in claim 9, wherein the first optical filter and the second optical filter together blocks substantially all light.
- A method as claimed in claim 9 which comprises inserting the assay device (1) into a reader (2) for detecting an output from the assay device (1), the reader (2) comprising a body having an orifice (35) that is capable of receiving the assay device (1), a light source (32) for illuminating the assay device (1) from said second side thereof once it has been received in the reader (2), an optical detector (34) located in the body for detecting light that has been emitted from first side of the assay device (1), and an arrangement (38,42) for detecting the optical power of light detected by the optical detector (34).
- A method as claimed in claim 9 which comprises illuminating the assay device (1) with white light from said second side thereof and observing from the first side thereof to determine the presence or quantity of analyte from the label material.
- A method as claimed in claim 13 wherein the white light is ambient light.
- A method as claimed in claim 13 or claim 14 wherein the label material comprises a fluorescent or phosphorescent material.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/221,381 US20130052748A1 (en) | 2011-08-30 | 2011-08-30 | Assay device and method of assaying |
GB1120356.9A GB2494211B (en) | 2011-08-30 | 2011-11-24 | Assay device with optical filters and method of assaying |
PCT/GB2012/000691 WO2013030524A1 (en) | 2011-08-30 | 2012-08-30 | Assay device comprising an optical filter and a method of assaying |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2766727A1 EP2766727A1 (en) | 2014-08-20 |
EP2766727B1 true EP2766727B1 (en) | 2015-10-07 |
Family
ID=45475720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12787472.5A Not-in-force EP2766727B1 (en) | 2011-08-30 | 2012-08-30 | Assay device comprising an optical filter and a method of assaying |
Country Status (8)
Country | Link |
---|---|
US (1) | US20130052748A1 (en) |
EP (1) | EP2766727B1 (en) |
JP (1) | JP6096779B2 (en) |
CN (2) | CN107064139A (en) |
BR (1) | BR112014004698A2 (en) |
ES (1) | ES2555109T3 (en) |
GB (1) | GB2494211B (en) |
WO (1) | WO2013030524A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10816550B2 (en) | 2012-10-15 | 2020-10-27 | Nanocellect Biomedical, Inc. | Systems, apparatus, and methods for sorting particles |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
GB2523135A (en) * | 2014-02-13 | 2015-08-19 | Molecular Vision Ltd | Assay device |
WO2016015701A1 (en) | 2014-07-31 | 2016-02-04 | Schebo Biotech Ag | Bioanalysis device, the production thereof and method for detecting bioanalytes by means of the device |
USD773685S1 (en) * | 2015-04-24 | 2016-12-06 | Accelerate Diagnostics, Inc. | Cartridge |
USD771834S1 (en) * | 2015-04-28 | 2016-11-15 | University Of British Columbia | Microfluidic cartridge |
USD841186S1 (en) * | 2015-12-23 | 2019-02-19 | Tunghai University | Biochip |
CN115487880A (en) | 2016-03-24 | 2022-12-20 | 生物动力学公司 | Disposable fluidic cartridge and assembly |
USD800336S1 (en) * | 2016-07-13 | 2017-10-17 | Precision Nanosystems Inc | Microfluidic cartridge |
USD812242S1 (en) * | 2016-07-13 | 2018-03-06 | Precision Nanosystems Inc | Microfluidic cartridge |
USD814652S1 (en) * | 2016-10-14 | 2018-04-03 | Spartan Bioscience In. | Cartridge |
CA3046461A1 (en) | 2016-12-09 | 2018-06-14 | Nowdiagnostics, Inc. | Diagnostic testing assays and related devices with security and methods of use thereof |
WO2018208820A1 (en) | 2017-05-08 | 2018-11-15 | Biological Dynamics, Inc. | Methods and systems for analyte information processing |
AU2018388641B2 (en) | 2017-12-19 | 2023-09-07 | Biological Dynamics, Inc. | Methods and devices for detection of multiple analytes from a biological sample |
CN117065932A (en) | 2018-04-02 | 2023-11-17 | 生物动力学公司 | Dielectric material |
CN109142252A (en) * | 2018-09-29 | 2019-01-04 | 重庆迈联医疗科技有限公司 | A kind of modular lipids detection instrument |
KR102039998B1 (en) * | 2019-07-17 | 2019-11-27 | 한성대학교 산학협력단 | Detection kit for hazardous substance based on water soluble polymer scaffold |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5837546A (en) * | 1993-08-24 | 1998-11-17 | Metrika, Inc. | Electronic assay device and method |
US5891649A (en) * | 1996-08-08 | 1999-04-06 | California Institute Of Technology | Real-time biochemical assay telemetering system |
AU5646800A (en) * | 1999-03-02 | 2000-09-21 | Helix Biopharma Corporation | Card-based biosensor device |
DE10042023C2 (en) | 2000-08-08 | 2003-04-10 | Biognostic Ag | Capsules that encapsulate solid particles of signal-generating substances and their use in bioassays for the detection of target molecules in a sample |
US7524459B2 (en) * | 2002-01-24 | 2009-04-28 | California Institute Of Technology In Pasadena | Optoelectronic and microfluidic integration for miniaturized spectroscopic devices |
AU2003248273A1 (en) * | 2002-07-12 | 2004-02-02 | Mitsubishi Chemical Corporation | Analytical chip, analytical chip unit, analyzing apparatus, method of analysis using the apparatus, and method of producing the analytical chip |
KR100639776B1 (en) * | 2004-01-05 | 2006-10-27 | 바이오메드포토닉스 주식회사 | A method for the detection of lateral flow assay and strip and Laser-induced Epifluorescence and compact scanner therefor |
US8105849B2 (en) * | 2004-02-27 | 2012-01-31 | Board Of Regents, The University Of Texas System | Integration of fluids and reagents into self-contained cartridges containing sensor elements |
US7521259B2 (en) * | 2004-04-01 | 2009-04-21 | Alverix, Inc. | Assay test strips with multiple labels and reading same |
US7796266B2 (en) * | 2004-04-30 | 2010-09-14 | Kimberly-Clark Worldwide, Inc. | Optical detection system using electromagnetic radiation to detect presence or quantity of analyte |
US20070121113A1 (en) * | 2004-12-22 | 2007-05-31 | Cohen David S | Transmission-based optical detection systems |
WO2007098184A2 (en) * | 2006-02-21 | 2007-08-30 | Nanogen, Inc. | Methods and compositions for analyte detection |
US20080102473A1 (en) * | 2006-10-31 | 2008-05-01 | Fouquet Julie E | Method and system to improve contrast in lateral flow assay |
US9945789B2 (en) * | 2007-01-16 | 2018-04-17 | Alverix, Inc. | Multiple analyte detection systems and methods of detecting multiple analytes |
CN103154735B (en) * | 2009-05-11 | 2018-10-02 | 连接Dx股份有限公司 | Method and composition for testing and analyzing object |
CN101726596A (en) * | 2009-11-04 | 2010-06-09 | 无锡中德伯尔生物技术有限公司 | Fluorescent microsphere immunochromatographic testing card for testing five indexes of hepatitis b and method for preparing same |
-
2011
- 2011-08-30 US US13/221,381 patent/US20130052748A1/en not_active Abandoned
- 2011-11-24 GB GB1120356.9A patent/GB2494211B/en not_active Expired - Fee Related
-
2012
- 2012-08-30 ES ES12787472.5T patent/ES2555109T3/en active Active
- 2012-08-30 JP JP2014527729A patent/JP6096779B2/en not_active Expired - Fee Related
- 2012-08-30 EP EP12787472.5A patent/EP2766727B1/en not_active Not-in-force
- 2012-08-30 CN CN201611258951.4A patent/CN107064139A/en active Pending
- 2012-08-30 WO PCT/GB2012/000691 patent/WO2013030524A1/en active Application Filing
- 2012-08-30 CN CN201280052574.2A patent/CN104040340A/en active Pending
- 2012-08-30 BR BR112014004698A patent/BR112014004698A2/en not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10816550B2 (en) | 2012-10-15 | 2020-10-27 | Nanocellect Biomedical, Inc. | Systems, apparatus, and methods for sorting particles |
Also Published As
Publication number | Publication date |
---|---|
EP2766727A1 (en) | 2014-08-20 |
US20130052748A1 (en) | 2013-02-28 |
GB2494211A (en) | 2013-03-06 |
WO2013030524A1 (en) | 2013-03-07 |
JP6096779B2 (en) | 2017-03-15 |
GB201120356D0 (en) | 2012-01-04 |
GB2494211B (en) | 2015-01-07 |
CN107064139A (en) | 2017-08-18 |
BR112014004698A2 (en) | 2017-12-12 |
ES2555109T3 (en) | 2015-12-29 |
JP2014525577A (en) | 2014-09-29 |
CN104040340A (en) | 2014-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2766727B1 (en) | Assay device comprising an optical filter and a method of assaying | |
EP1634062B1 (en) | Readhead for optical inspection apparatus | |
EP1582598B1 (en) | Optoelectronic rapid diagnostic test system | |
US9606115B2 (en) | Analyte detection methods and devices | |
WO2005111578A1 (en) | Techniques for controlling the optical properties of assay devices | |
AU2013225728A1 (en) | Interactive test device and apparatus with timing mechanism | |
KR20090051060A (en) | Transmission-based optical detection systems | |
JPH09504872A (en) | Test strip reader | |
WO2017108726A1 (en) | Optical detection of a substance in fluid | |
EP3324175B1 (en) | Biological assay sample analyzer | |
US20210208075A1 (en) | Autofluorescence quenching assay and device | |
US8570518B2 (en) | Methods and materials for detection of target species | |
CA3011339A1 (en) | Performing one or more analyses on a thin layer of biologic fluid using optically responsive chemical sensors | |
WO2012042117A1 (en) | A device for holding a sample | |
CN116829925A (en) | Optical module | |
WO2024070698A1 (en) | Immunochromatographic cartridge | |
WO2024070697A1 (en) | Immunochromatography testing device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140320 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602012011406 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: G01N0033520000 Ipc: G01N0021840000 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/558 20060101ALI20150506BHEP Ipc: G01N 21/84 20060101AFI20150506BHEP Ipc: G01N 33/53 20060101ALI20150506BHEP Ipc: G01N 33/52 20060101ALI20150506BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150612 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
INTG | Intention to grant announced |
Effective date: 20150813 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 754039 Country of ref document: AT Kind code of ref document: T Effective date: 20151015 Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE , CH Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012011406 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2555109 Country of ref document: ES Kind code of ref document: T3 Effective date: 20151229 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20151007 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 754039 Country of ref document: AT Kind code of ref document: T Effective date: 20151007 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160207 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160107 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160108 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160208 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602012011406 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 |
|
26N | No opposition filed |
Effective date: 20160708 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160830 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160830 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20120830 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160831 Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151007 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20180921 Year of fee payment: 7 Ref country code: FR Payment date: 20180817 Year of fee payment: 7 Ref country code: IT Payment date: 20180827 Year of fee payment: 7 Ref country code: DE Payment date: 20180814 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20180816 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602012011406 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190831 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190831 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200303 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190830 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20210108 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190831 |